{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:42:13Z","timestamp":1740163333895,"version":"3.37.3"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008130","name":"Helsinn Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s13555-022-00831-w","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T19:13:08Z","timestamp":1666725188000},"page":"2781-2795","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Maintenance and Concomitant Therapy Use with Chlormethine Gel Among Patients with Stage IA\/IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Real-World Evidence Study"],"prefix":"10.1007","volume":"12","author":[{"given":"Christiane","family":"Querfeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winnie W.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deval","family":"Gor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris L.","family":"Pashos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan V.","family":"Doan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Turini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James T.","family":"Angello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larisa J.","family":"Geskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"key":"831_CR1","unstructured":"VALCHOR [package insert]. Helsinn Therapeutics US, Inc., 2020."},{"key":"831_CR2","unstructured":"Ledaga. INN\u2014chlormethine; Annex I, Summary of product characteristics. European Medicines Agency. [cited 2022 June 28]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ledaga-epar-product-information_en.pdf."},{"issue":"4","key":"831_CR3","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s13555-021-00539-3","volume":"11","author":"LJ Geskin","year":"2021","unstructured":"Geskin LJ, et al. Chlormethine gel for the treatment of skin lesions in all stages of mycosis fungoides cutaneous T-cell lymphoma: a narrative review and international experience. Dermatol Ther (Heidelb). 2021;11(4):1085\u2013106.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"831_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40257-021-00591-x","volume":"22","author":"EJ Kim","year":"2021","unstructured":"Kim EJ, et al. The PROVe study: US real-world experience with chlormethine\/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma. Am J Clin Dermatol. 2021;22(3):407\u201314.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"831_CR5","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jdcr.2020.05.031","volume":"6","author":"ES Gilmore","year":"2020","unstructured":"Gilmore ES, et al. Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis. JAAD Case Rep. 2020;6(9):878\u201381.","journal-title":"JAAD Case Rep"},{"key":"831_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.679294","author":"C Querfeld","year":"2021","unstructured":"Querfeld C, et al. A little experience goes a long way: chlormethine\/mechlorethamine treatment duration as a function of clinician-level patient volume for mycosis fungoides cutaneous T-Cell lymphoma (MF-CTCL)\u2014a retrospective cohort study. Front Med. 2021. https:\/\/doi.org\/10.3389\/fmed.2021.679294.","journal-title":"Front Med"},{"key":"831_CR7","unstructured":"NCCN. Clinical practice guidelines in oncology. Primary cutaneous lymphoma. Version 1.2022. 2022 April 2022]. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/primary_cutaneous.pdf"},{"key":"831_CR8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.clml.2022.02.002","volume":"22","author":"E Correia","year":"2022","unstructured":"Correia E, et al. Response to chlormethine\/mechlorethamine gel maintenance treatment regimen in patients with mycosis fungoides: a single-center retrospective study. Clin Lymphoma Myeloma Leuk. 2022;22:581\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00831-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00831-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00831-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T20:50:00Z","timestamp":1668804600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00831-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":8,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["831"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00831-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2022,10,25]]},"assertion":[{"value":"25 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}